Sign in
WithdrawnPhase 1

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Key facts

Who runs it
Codagenix, Inc
Where
Boston and Canton, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Phase
Phase 1
Started
15 Jan 2023
Ended
30 Jan 2025
Type of study
Interventional, 4 groups
Treatments tested
  • CodaLytic
Record updated
18 October 2023
Why it stopped
Due to funding decision by the sponsor

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Women or men with metastatic or inoperable, histologically confirmed breast cancer
  • Has no alternative treatment of proven benefit available or has refused treatment
  • Expected survival ≥ 3 months
  • At least 2 measurable lesions according to RECIST 1.1, without contraindication for repeated injections and core needle biopsies
  • Adequate organ function
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • Negative pregnancy test, if female
  • Agreement to practice a highly effective method of contraception
  • Agreement to no sperm donation through 28 days, if male
  • Willing to provide consent to perform study procedures

Who cannot take part

  • Anticancer therapy within 3 weeks of dosing
  • Presence of a concurrent malignancy for which the natural history or treatment has the potential to interfere with the safety or efficacy assessment of the Investigational Product
  • Immunodeficiency or use of therapies expected to impair the immune response within thirty (30) days of enrollment or during dosing
  • Ongoing toxicity > Grade 1 from prior treatment except those which are stable
  • Planned radiation to lesions targeted for assessment/injection within 60 days before first dose or any planned radiation during dosing period
  • Uncontrolled or severe cardiovascular disease
  • History of severe reaction (ie, anaphylaxis) to vaccination or immunotherapy
  • Any condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a participant's ability to give informed consent
  • Pregnant or lactating women
  • Known active central nervous system metastases (with some exceptions)

Where in United States

  • Dana-Farber Cancer InstituteBoston, United States
  • Gabrail Cancer CenterCanton, United States

About the trial

What the trial wants to find out

The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast cancer.

Read full original descriptionShow less

The main questions it aims to answer are:

* How safe is CodaLytic when administered in escalating dosing groups into targeted lesions? * What is the impact of CodaLytic on lesion response and disease progression?

Eligible participants will be enrolled into four (4) escalating dose groups and treated with Codalytic through injection into a selected lesion(s) over twelve (12) weeks and then followed for up to one (1) year after the first dose. A safety committee will review the safety profile of each dosing group before the next dose-escalation.

Study procedures will include physical examinations, injection site assessments, biopsies, imaging, and collection of blood/urine to assess safety, the body's immune response, and efficacy.

The 4 groups in the trial

  • 10e7 PFU dose 3 injectionsTreatment being tested

    10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)

    Treatment: CodaLytic

  • 10e7 PFU dose 5 injectionsTreatment being tested

    10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)

    Treatment: CodaLytic

  • 10e8 PFU dose 3 injectionsTreatment being tested

    10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)

    Treatment: CodaLytic

  • 10e8 PFU dose 5 injectionsTreatment being tested

    10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)

    Treatment: CodaLytic

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer
Record updated
18 October 2023